Aptorum Group (APM) Competitors $0.74 +0.00 (+0.09%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APM vs. NERV, GLYC, BGXX, BTAI, NRXP, CARA, AIM, ACXP, TXMD, and HCWBShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Minerva Neurosciences (NERV), GlycoMimetics (GLYC), Bright Green (BGXX), BioXcel Therapeutics (BTAI), NRx Pharmaceuticals (NRXP), Cara Therapeutics (CARA), AIM ImmunoTech (AIM), Acurx Pharmaceuticals (ACXP), TherapeuticsMD (TXMD), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Minerva Neurosciences GlycoMimetics Bright Green BioXcel Therapeutics NRx Pharmaceuticals Cara Therapeutics AIM ImmunoTech Acurx Pharmaceuticals TherapeuticsMD HCW Biologics Minerva Neurosciences (NASDAQ:NERV) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Does the MarketBeat Community believe in NERV or APM? Minerva Neurosciences received 306 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 57.64% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34757.64% Underperform Votes25542.36% Aptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Do analysts prefer NERV or APM? Minerva Neurosciences presently has a consensus price target of $5.00, suggesting a potential upside of 131.48%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor NERV or APM? In the previous week, Aptorum Group had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Aptorum Group and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.00 beat Aptorum Group's score of -0.71 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders and institutionals hold more shares of NERV or APM? 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, NERV or APM? Minerva Neurosciences has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Which has stronger valuation & earnings, NERV or APM? Aptorum Group has higher revenue and earnings than Minerva Neurosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M-$0.44-4.91Aptorum Group$431.38K8.89-$2.83MN/AN/A Is NERV or APM more profitable? Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Aptorum Group N/A N/A N/A SummaryAptorum Group beats Minerva Neurosciences on 7 of the 12 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.83M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5589.7417.16Price / Sales8.89196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book0.255.094.784.78Net Income-$2.83M$151.83M$120.31M$225.60M7 Day Performance-3.48%-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year Performance-64.76%8.87%28.34%15.24% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.3987 of 5 stars$0.74+0.1%N/A-66.2%$3.83M$431,378.000.0030News CoverageNERVMinerva Neurosciences3.467 of 5 stars$2.23+0.9%$5.00+124.2%-67.0%$15.59MN/A-5.029Analyst ForecastNews CoverageGap DownGLYCGlycoMimetics4.228 of 5 stars$0.24+1.3%$10.00+4,035.6%-89.0%$15.59M$10,000.000.0050News CoverageGap DownBGXXBright GreenN/A$0.08-11.7%N/A-82.3%$15.29MN/A-1.512Gap UpBTAIBioXcel Therapeutics3.9882 of 5 stars$0.35-15.1%$5.00+1,328.6%-88.5%$14.96M$2.28M-0.1790Negative NewsGap DownHigh Trading VolumeNRXPNRx Pharmaceuticals3.2971 of 5 stars$1.19-1.2%$32.00+2,598.1%-96.5%$14.34MN/A-0.562News CoveragePositive NewsCARACara Therapeutics4.2299 of 5 stars$0.26-2.7%$2.32+809.8%-29.0%$13.99M$8.69M-0.1555News CoverageGap DownAIMAIM ImmunoTech2.3707 of 5 stars$0.22+0.1%$2.75+1,154.0%-60.4%$13.99M$190,000.00-0.4720ACXPAcurx Pharmaceuticals1.3843 of 5 stars$0.82-4.1%$12.00+1,363.4%-77.0%$13.85MN/A-0.783Gap UpTXMDTherapeuticsMD0.4365 of 5 stars$1.19-2.9%N/A-53.8%$13.66M$1.30M0.00420Analyst ForecastGap UpHCWBHCW Biologics0.4069 of 5 stars$0.36-0.5%N/A-60.4%$13.44M$3.50M-0.3640Gap Down Related Companies and Tools Related Companies NERV Competitors GLYC Competitors BGXX Competitors BTAI Competitors NRXP Competitors CARA Competitors AIM Competitors ACXP Competitors TXMD Competitors HCWB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
